Cheung Onpan, Puri Puneet, Eicken Christoph, Contos Melissa J, Mirshahi Faridoddin, Maher James W, Kellum John M, Min Haeki, Luketic Velimir A, Sanyal Arun J
Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, VA, USA.
Hepatology. 2008 Dec;48(6):1810-20. doi: 10.1002/hep.22569.
The expression of microRNA in nonalcoholic steatohepatitis (NASH) and their role in the genesis of NASH are not known. The aims of this study were to: (1) identify differentially expressed microRNAs in human NASH, (2) tabulate their potential targets, and (3) define the effect of a specific differentially expressed microRNA, miR-122, on its targets and compare these effects with the pattern of expression of these targets in human NASH. The expression of 474 human microRNAs was compared in subjects with the metabolic syndrome and NASH versus controls with normal liver histology. Differentially expressed microRNAs were identified by the muParaflo microRNA microarray assay and validated using quantitative real-time polymerase chain reaction (PCR). The effects of a specific differentially expressed miRNA (miR-122) on its predicted targets were assessed by silencing and overexpressing miR-122 in vitro. A total of 23 microRNAs were underexpressed or overexpressed. The predicted targets of these microRNAs are known to affect cell proliferation, protein translation, apoptosis, inflammation, oxidative stress, and metabolism. The miR-122 level was significantly decreased in subjects with NASH (63% by real-time PCR, P < 0.00001). Silencing miR-122 led to an initial increase in mRNA levels of these targets (P < 0.05 for all) followed by a decrease by 48 hours. This was accompanied by an increase in protein levels of these targets (P < 0.05 for all). Overexpression of miR-122 led to a significant decrease in protein levels of these targets.
NASH is associated with altered hepatic microRNA expression. Underexpression of miR-122 potentially contributes to altered lipid metabolism implicated in the pathogenesis of NASH.
非酒精性脂肪性肝炎(NASH)中微小RNA的表达及其在NASH发病机制中的作用尚不清楚。本研究的目的是:(1)鉴定人类NASH中差异表达的微小RNA,(2)列出其潜在靶点,(3)确定一种特定的差异表达微小RNA,即miR-122,对其靶点的影响,并将这些影响与这些靶点在人类NASH中的表达模式进行比较。在患有代谢综合征和NASH的受试者与肝脏组织学正常的对照组中比较了474种人类微小RNA的表达。通过muParaflo微小RNA微阵列分析鉴定差异表达的微小RNA,并使用定量实时聚合酶链反应(PCR)进行验证。通过在体外沉默和过表达miR-122来评估一种特定的差异表达微小RNA(miR-122)对其预测靶点的影响。共有23种微小RNA表达下调或上调。已知这些微小RNA的预测靶点会影响细胞增殖、蛋白质翻译、细胞凋亡、炎症、氧化应激和代谢。NASH患者的miR-122水平显著降低(实时PCR检测降低63%,P<0.00001)。沉默miR-122导致这些靶点的mRNA水平最初升高(所有P<0.05),随后在48小时时下降。这伴随着这些靶点的蛋白质水平升高(所有P<0.05)。miR-122的过表达导致这些靶点的蛋白质水平显著降低。
NASH与肝脏微小RNA表达改变有关。miR-122的低表达可能导致NASH发病机制中涉及的脂质代谢改变。